AI Stock Memo: GSK - GSK - RankAlpha

GSK

Rating sellAI Memo

GSK

As of 2026-01-31/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-31 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

sell

Confidence

high

Horizon

—

Key catalyst

FY2025 results and guidance release • 2026-02-04

Expected move: -7%

Biggest risk

Earnings or guidance miss, adverse regulatory decisions, or material pipeline failures trigger a steep re-rating toward the low ($15 in analyst universe), amplified by investor rotation out of defensive healthcare positions.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

Execution on late‑stage pipeline readouts and positive FY2026 guidance drive re-rating to analyst high (near $53); successful commercial traction and favorable regulatory outcomes widen multiples.

Research note

Recommendation

sell

Confidence

high

As of

2026-01-31

Base target

$46

p=60%

Bull target

$53

p=15%

Bear target

$15

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings analyst target revisions
Consensus re-rating driven by strategy/pipeline execution
Execution on late‑stage pipeline readouts and positive FY2026 guidance drive re-rating to analyst high (near $53); successful commercial traction and favorable regulatory outcomes widen multiples.

BearKey bullets

Adverse clinical or regulatory outcomes for key pipeline assets
Earnings/guidance miss on 2026-02-04
Macro/currency impacts on UK-based reporting and dividends

WatchKey bullets

FY2025 results and guidance release

Summary

High-level snapshot

Recommendation

sell

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $46 (p=60%)

Bull/Bear spread: +8% / -69%

Vs latest close: Bull +8% · Base -7% · Bear -69%

Scenario probabilities

Bull Target: $53 (p=15%)Base Target: $46 (p=60%)Bear Target: $15 (p=25%)

Commentary

Market snippets show mixed-to-cautious analyst views with a median below current market price, signaling modest downside in base case [#SERP-1]. Some outlets report higher individual targets near $53, creating a narrow upside band versus a wide downside distribution in lower estimates [#SERP-3][#SERP-4]. Overall tone: cautious ahead of FY2025 results with attention on post-earnings revisions.

As of 2026-01-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Execution on late‑stage pipeline readouts and positive FY2026 guidance drive re-rating to analyst high (near $53); successful commercial traction and favorable regulatory outcomes widen multiples.

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings analyst target revisions
Consensus re-rating driven by strategy/pipeline execution

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-31Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$45.50

Range (USD)

$15.00 - $53.00

Count

Query: GSK plc ADR (GSK) analyst consensus price target high low average

GSK PLC ADR Analyst Estimates - MarketWatch
Search result #1
Stock Price Targets. High, $25.70. Median, $18.00. Low, $15.00. Average, $18.79. Current Price, $50.66. Yearly Numbers. Estimates. GSK will report 2025 earnings ...
Extracted: $25.70, $18.00, $15.00, $18.79, $50.66Open source
Glaxo (GSK) Stock Forecast & Price Target - Investing.com
Search result #2
According to projections from 20 analysts, the average 12-month price target for GSK plc is 1,877.80, with a high estimate of 2570 and a low estimate of ...
Open source
GSK (GSK) Stock Forecast and Price Target 2026 - MarketBeat
Search result #3
The highest price target for GSK is $53.00, while the lowest price target for GSK is $35.25. The average price target represents a forecasted downside of -14. ...
Extracted: $53.00, $35.25Open source
GSK PLC ADR Research & Ratings - Barron's
Search result #4
ConsensusHoldHoldHold. Stock Price Target. High, $52.00. Low, $47.00. Average, $49.10. Current Price, $50.32. GSK will report FY 2025 earnings on 02/04/2026 ...
Extracted: $52.00, $47.00, $49.10, $50.32Open source
GSK Stock Price | Analyst Target 52.00 & Hold Consensus - eToro
Search result #5
The average price target for GlaxoSmithKline plc ADR is ‎$‎52.00. Sign up to eToro for detailed analyst forecasts and price targets.
Open source
GSK plc (GSK) Analyst Ratings, Estimates & Forecasts
Search result #6
See GSK plc (GSK) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source

Scenarios

Bull Target (Scenario probability)

$53 / p=15% prob

Base Target (Scenario probability)

$46 / p=60% prob

Bear Target (Scenario probability)

$15 / p=25% prob

Price $49 as of 2026-06-02

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +8% · Base -7% · Bear -69%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-02-04
FY2025 results and guidance release
GSK to report FY2025 results and any guidance updates (market pages note FY2025 results expected 2026-02-04) — market reaction likely; see consensus reporting [#SERP-4].
Prob 90.00% • Move 6.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Post-earnings analyst target revisions
2026-04-30
Analysts historically update 1–4 weeks after results; expect target/estimate revisions and note changes to median/high/low (assumption: review window ends by 2026-04-30) — informed by analyst target aggregators [#SERP-1],[#SERP-4].
Prob 60% • Move 8% • Priced-in 25%

Long-term Catalysts

Months to a year

Consensus re-rating driven by strategy/pipeline execution
2027-01-31
Over 12 months, successful pipeline readouts, portfolio execution or sustained sales growth could push consensus toward the high end; see GSK analyst consensus bulletin [#SERP-8].
Prob 55% • Move 20% • Priced-in 20%

Risks

Adverse clinical or regulatory outcomes for key pipeline assets
Earnings/guidance miss on 2026-02-04
Macro/currency impacts on UK-based reporting and dividends
Material analyst downgrades / consensus target cuts

Peers

Symbol	Summary
SNY	Large diversified pharma with comparable vaccine and Rx exposure; relevant for R&D and label/regulatory dynamics.
AZN	Large oncology/respiratory portfolio and commercial scale; useful comparator for growth vs. GSK's pipeline cadence.
PFE	Broad pharma/biotech exposure with vaccine capability; peer for commercialization and supply-chain risks.
JNJ	Diversified healthcare conglomerate; useful for cross-segment margin and portfolio resilience comparisons.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: GSK plc ADR (GSK) analyst consensus price target high low average
Analysis date: 2026-01-31